BONE MINERAL DENSITY IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY

BONE MINERAL DENSITY IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY - BMD during ADT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37103

Enrollment

Registered

2012-12-19

Start date

2013-06-26

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone loss osteoporosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Prostate cancer androgen deprivation according to Bolla schedule

Exclusion criteria

Exclusion criteria: osteoporosis treatment with bisphophonates or RANK-ligand inhibitor

Design outcomes

Primary

Measure	Time frame
Compare the change in BMD between the 2 modalities	—

Secondary

Measure	Time frame
describe course of BMD of both modalities Identify factors that influence the BMD pattern	—

Countries

Netherlands

Outcome results